11 Clinical Trials on Triple GLP-1/GIP/Glucagon Agonists Retatrutide: A Triple Agonist for Maximum Weight Loss Retatrutide (LY3437943) is a triple incretin receptor agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, and is designed to maximize weight loss and metabolic improvement through complementary hormonal pathways
Specifically, the combination of BPC-157s gastrointestinal cytoprotection, GHK-Cus extracellular matrix remodeling, TB-500s cellular migration, and KPVs anti-inflammatory resolution addresses all four phases of gut mucosal healing in a single preparation
All analyses were conducted with Review Manager, version 5.4 (Nordic Cochrane Centre, Copenhagen, Denmark)
This variation in pharmacokinetics across GLP-1 is critical when considering each drugs suitability for pregnancy, as it directly impacts blood glucose control, convenience, and potential adherence in GDM management
N Engl J Med 2021;384:111324.ArticlePubMed 81
Precursors include N-acetylcysteine (NAC), alpha-lipoic acid (ALA), and whey protein